Ask AI
HER2 Positive GEA and BTC IDST
Interactive Decision Support Tool: HER2-Positive GEA and BTC Treatment Guidance

Released: April 24, 2026

About This Tool & Disclaimer

Interactive Decision Support Tool: HER2-Positive GEA and BTC Treatment Guidance

Decera Clinical Education is grateful to Richard Kim, MD; Geoffrey Ku, MD; Amit Mahipal, MD, MPH; Shubham Pant, MD; and Rachna T. Shroff, MD, MS, FASCO, who provided expert guidance, knowledge, and support in the development of this Interactive Decision Support Tool.

Note: The current tool was created in April 2026 and reflects the guidelines available at that time.

The goal of the tool is to educate healthcare professionals on making optimal management choices for the treatment of individuals with HER2-positive locally advanced, unresectable or metastatic gastroesophageal adenocarcinoma (GEA) and biliary tract cancer (BTC).

A series of questions allows the participant to select individual patient characteristics that are necessary to consider when making management choices. These characteristics include HER2 protein expression level, programmed death-ligand 1 (PD-L1) protein expression status, Eastern Cooperative Oncology Group performance status, prior therapies, and specific comorbidities.

It should be noted that these are not exclusive characteristics when selecting optimal treatment for patients with locally advanced, unresectable or metastatic GEA and BTC. Other patient-specific and disease-specific considerations that are not included in this tool, such as the presence of various other comorbidities, actionable biomarkers that may be co-occurring with HER2 overexpression/amplification and any concurrent medications, should also be considered, when appropriate, for making management decisions.

This tool assumes we have a patient with HER2-positive advanced GEA or BTC but with no additional features or specific comorbidities that would affect treatment choice other than those described when entering the patient details. Based on the characteristics entered, the tool will display guideline-based expert recommendations for that specific patient case.

For additional information on best practices in the management of patients with HER2-positive advanced GEA or BTC, please view our certified on-demand webcast from a live webinar titled, "Innovations in HER2+ Gastroesophageal Adenocarcinoma and Biliary Tract Cancer: A Practical Skills Course on New and Emerging Targeted Therapies," download the accompanying slideset and patient resource, see our certified interactive case challenges, listen to the podcasts, and read the expert-authored commentary by Amit Mahipal, MD, MPH; Shubham Pant, MD; Richard Kim, MD; and Kristy Rostocil, AGACNP-BC.

This program is supported by an educational grant from Jazz Pharmaceuticals, Inc.

Produced in partnership with Smart Patients, Inc.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Richard Kim, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, Bayer, Eisai, Elevar, Exelixis, Incyte, Ipsen, Jazz, Roche, Servier, Taiho, Takeda.

Geoffrey Ku, MD: researcher: AstraZeneca, Bristol Myers Squibb, CARsgen, Daiichi Sankyo, I-Mab, Jazz, Merck, Oncolys, Pieris, Triumvira, Zymeworks; consultant/advisor/speaker: Astellas, AstraZeneca, Bayer, BeOne, Bristol Myers Squibb, Daiichi Sankyo, Gilead, I-Mab, Jazz, Merck, Oncolys, Pieris, Zymeworks; other financial or material support: Dava Oncology, I-Mab.

Amit Mahipal, MD, MPH: consultant/advisor/speaker: Astellas, AstraZeneca, Jazz.

Shubham Pant, MD: consultant/advisor/speaker: AskGene, AstraZeneca, BPGBio, Ipsen, Jazz, Janssen, Novartis, Zymeworks; researcher (paid to institution): Arcus, Boehringer Ingelheim, Bristol Myers Squibb, Elicio, Ipsen, Janssen, Lilly, Novartis, Pfizer, Zymeworks; equity: Telperian.

Rachna T. Shroff, MD, MS, FASCO: consultant/advisor/speaker: AstraZeneca, Boehringer Ingelheim, Boston Scientific, Elevar, Exelixis, Foundation Medicine, Genentech, J-Pharma Co, Merck, Servier, Syneos Health, Zymeworks; researcher: Actuate, Bristol Myers Squibb, Compass, Exelixis, Faeth, Immuno Vaccine, Lisata, Merck, Seagen.

© 2026 Decera Clinical Education. All rights reserved.

Access to and use of this Interactive Decision Support Tool titled, “Interactive Decision Support Tool: HER2-Positive GEA and BTC Treatment Guidance” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate healthcare professionals on making optimal management choices for monitoring or treating individuals with HER2-positive advanced GEA and BTC. The information provided is based on guideline recommendations and expert guidance of Richard Kim, MD; Geoffrey Ku, MD; Amit Mahipal, MD, MPH; Shubham Pant, MD; and Rachna T. Shroff, MD, MS, FASCO.

The material published by Decera Clinical Education reflects the views of the reviewers or authors of the material, not those of Decera Clinical Education, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the FDA. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “Interactive Decision Support Tool: HER2-Positive GEA and BTC Treatment Guidance” has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Decera Clinical Education provides this information on an as-is basis. This disclaimer applies to all material published by Decera Clinical Education including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

© 2026 Decera Clinical Education. All rights reserved.

Program Content